CIK 0001965040 · Services-Medical Laboratories (SIC 8071) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | |
|---|---|---|---|
| Revenue (USD) | 2.7 B | 2.8 B | |
| Net income (USD) | 186.2 M | 98.0 M | |
| Diluted EPS (USD/shares) | -10.81 | 2.09 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-09-30 | 8-K | 8-K items 5.02 | 2026-09-29 |
| 2026-09-14 | 4 | PRIMARY DOCUMENT | 2026-09-10 |
| 2026-09-11 | 144/A | 144/A | |
| 2026-09-11 | 144 | 144 | |
| 2026-09-10 | 4 | PRIMARY DOCUMENT | 2026-09-08 |
| 2026-09-10 | 4 | PRIMARY DOCUMENT | 2026-09-08 |
| 2026-09-10 | 144 | 144 | |
| 2026-09-10 | 8-K | 8-K items 5.02 | 2026-09-09 |
| 2026-09-09 | 144 | 144 | |
| 2026-09-09 | 144 | 144 | |
| 2026-09-09 | 144 | 144 | |
| 2026-08-19 | 4 | PRIMARY DOCUMENT | 2026-08-18 |
| 2026-08-19 | 144 | 144 | |
| 2026-08-19 | 144 | 144 | |
| 2026-08-17 | 3 | PRIMARY DOCUMENT | 2026-08-07 |
| 2026-08-07 | 4 | PRIMARY DOCUMENT | 2026-08-06 |
| 2026-08-06 | 4 | PRIMARY DOCUMENT | 2026-08-04 |
| 2026-08-06 | 144 | 144 | |
| 2026-08-05 | 4 | PRIMARY DOCUMENT | 2026-08-03 |
| 2026-08-05 | 4 | PRIMARY DOCUMENT | 2026-08-03 |
| 2026-08-05 | 144 | 144 | |
| 2026-08-03 | 144 | 144 | |
| 2026-07-29 | 10-Q | 10-Q | 2026-06-30 |
| 2026-07-29 | 8-K | 8-K items 2.02,5.02,9.01 | 2026-07-27 |
| 2026-07-27 | 4 | PRIMARY DOCUMENT | 2026-07-20 |
Forms on file (last 1,000): 4 138, 144 44, 8-K 42, 3 22, SCHEDULE 13G/A 15, 10-Q 10, SCHEDULE 13G 7, 4/A 6. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=FTRE (0.002 USD), /gw/filings/filings?ticker=FTRE&form=8-K, /gw/filings/facts?ticker=FTRE&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange